NIHON MEDI-PHYSICS CO., LTD. Patent applications |
Patent application number | Title | Published |
20150063670 | Extraction of Myocardial Contour Points - One of the preferred embodiments includes: (a) creating a summed 3D nuclear medicine imaging data by summing a plurality of 3D nuclear medicine imaging data pixel by pixel; (b) determining pixels corresponding to myocardial regions in the summed 3D nuclear medicine imaging data; (c) defining a plurality of tracing directions based on the summed 3D nuclear medicine imaging data, and determining a reference myocardial center base point, a reference inner myocardial wall base point and a reference outer myocardial wall base point for each of the tracing directions; (d) determining a phase-specific myocardial center base point for each of the tracing directions for each of the phases; and (e) seeking a difference between the reference myocardial center base point and the phase-specific myocardial center base point, and determining a phase-specific inner myocardial wall base point and a phase-specific outer myocardial wall base point. | 03-05-2015 |
20140213817 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND - It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [ | 07-31-2014 |
20140187784 | RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME - It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof. | 07-03-2014 |
20140186261 | ANTI-TUMOR AGENT AND ANTI-TUMOR KIT - An anti-tumor agent comprising combination of a radioactive diacetyl-bis(N4-methylthiosemicarbazone) copper complex and a metabolic inhibitor. | 07-03-2014 |
20140186260 | RADIOPHARMACEUTICAL AND PHARMACEUTICAL KIT - A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less. | 07-03-2014 |
20140088306 | RADIOACTIVE FLUORINE-LABELED QUINOXALINE COMPOUND - Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound. | 03-27-2014 |
20130294671 | METHOD OF EXTRACTING CONTOUR OF TOMOGRAM, AND COMPUTER-READABLE STORAGE MEDIUM AND APPARATUS THEREFOR - Contour information is extracted from nuclear medicine projection data on a subject not subjected to a scattering correction and an absorption correction by performing a pixel value binarization processing based on a threshold scheme. If necessary, an interpolation processing is performed before reconstructing an image through an image reconstruction processing. Based on the reconstructed image, a second binarization processing is performed to generate a contour image. | 11-07-2013 |
20130251226 | APPARATUS FOR EVALUATING ACCURACY OF MEASUREMENT - A measuring image acquisition means | 09-26-2013 |
20120330024 | RADIOACTIVE IODINE LABELED ORGANIC COMPOUND OR SALT THEREOF - The present invention is a compound represented by the following formula (1) or a salt thereof. Furthermore, the present invention is an imaging agent used for imaging a tau protein, the imaging agent containing a compound represented by the formula (1) below or a salt thereof. In the formula (1), R | 12-27-2012 |
20120301399 | METHOD FOR PRODUCTION OF RADIATION DIAGNOSTIC IMAGING AGENT - A method for producing a radioactive diagnostic imaging agent containing a radioactive | 11-29-2012 |
20120271053 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID - The present invention provides a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagencity. Provided is a compound represented by the following formula (1) or a salt thereof: | 10-25-2012 |
20120128227 | DEVICE FOR GENERATING ALTERNATIVE OF NORMAL BRAIN DATABASE | 05-24-2012 |
20110201808 | NOVEL COMPOUND HAVING AFFINITY TO AMYLOID - The invention relates to a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagenicity, and also relates to a low-toxic diagnostic agent for Alzheimer's disease containing the compound. The compound is represented by the following formula (1) or a salt thereof: | 08-18-2011 |
20110188719 | TECHNIQUE FOR DETECTING NEURODEGENERATIVE DISORDERS - In one embodiment of the present invention, a significance test of pixel values is performed between a region where functions could be deteriorated in a disease-specific manner and a region where functions could be preserved even in cases of diseases using brain functional images. Then, the mean pixel value of the functionally preserved site is significantly greater than the mean pixel value of the functionally deteriorated site according to the significance test is determined as an a image including a neurodegenerative disorder. According to this embodiment, it becomes possible to objectively detect images of neurodegenerative disorders without using a database for healthy subjects. | 08-04-2011 |
20110172522 | DEVICE FOR CREATING DATABASE OF ALTERNATIVE NORMAL BRAIN | 07-14-2011 |
20110003981 | PROCESS FOR PRODUCING RADIOACTIVE FLUORINE LABELED ORGANIC COMPOUND, AND RELEVANT SYNTHETIC APPARATUS AND PROGRAM - A method of producing a radioactive-fluorine-labeled compound has a step of heating in a reaction vessel a mixture containing [ | 01-06-2011 |
20110002521 | CEREBRAL BLOOD FLOW QUANTIFICATION DEVICE, CEREBRAL BLOOD FLOW QUANTIFICATION METHOD AND PROGRAM - A cerebral blood flow rate quantification device includes: a nuclear medicine image acquisition unit for acquiring a nuclear medicine image of the head of a subject administered with a radiopharmaceutical; a count calculation unit for calculating the number of counts obtained from a unit region; a cerebral blood flow rate calculation unit for calculating the value of a cerebral blood flow rate that makes the value of a function, which expresses the concentration of the radiopharmaceutical in brain tissue; and a cerebral blood flow map generation unit for generating a map showing cerebral blood flow based on the cerebral blood flow rate in each unit region. Consequently, the cerebral blood flow rate can be accurately quantified even at a relatively early stage after administration of a radiopharmaceutical. | 01-06-2011 |
20100292479 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID - A compound effective as a probe targeting amyloid for image diagnosis and a reagent comprising the compound for detecting amyloid deposited on a biological tissue are provided. Provided are a compound represented by the following formula (1): | 11-18-2010 |
20100284584 | IMAGE PROCESSING PROGRAM, IMAGE PROCESSING METHOD AND IMAGE PROCESSOR - An image processing apparatus includes: a cutoff frequency table storing information on a relation between a parameter related to a radial intensity distribution of two-dimensional frequency components of a projection image and a Butterworth filter cutoff frequency to be applied to the projection image concerned; a projection image data input unit for inputting projection image data; an FFT unit for applying a two-dimensional Fourier transform to the projection image to obtain a spatial frequency of the projection image; a radial intensity distribution calculation unit for calculating a radial intensity distribution of frequency components of the projection image; a cutoff frequency setting unit for setting a cutoff frequency corresponding to a parameter related to the radial intensity distribution determined for the projection image, with reference to the cutoff frequency table; and a Butterworth filter for filtering the projection image data with the set cutoff frequency. | 11-11-2010 |
20100267952 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME - The invention provides a reagent for detecting amyloid in a biological tissue which can be detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagenicity. The reagent for detecting amyloid deposited in a biological tissue comprises a compound represented by the following formula (1) or a salt thereof: | 10-21-2010 |
20100261931 | PROCESS FOR PRODUCTION OF RADIOACTIVE-FLUORINE-LABELED ORGANIC COMPOUND - A process for production of a radioactive fluorine-labeled organic compound is provided which can improve the yield of radioactive fluorination. Provided is a process in which a compound represented by the following formula (1): | 10-14-2010 |
20100249419 | UTILIZATION OF NOVEL COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF PRODUCING THE SAME - The invention provides a reagent for detecting amyloid deposited in a biological tissue which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagencity. The reagent for detecting amyloid deposited in a biological tissue comprises a compound represented by the following formula (1) or a salt thereof: | 09-30-2010 |
20100249418 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID - A compound effective as a probe targeting amyloid for image diagnosis and a reagent comprising the compound for detecting amyloid deposited on a biological tissue are provided. Provided are a compound represented by the following formula (1): | 09-30-2010 |
20100249408 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME - The invention provides a reagent for detecting amyloid in a biological tissue which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagenicity. | 09-30-2010 |
20100249407 | Novel Compound Having Affinity to Amyloid - The invention relates to a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagenicity, and also relates to a low-toxic diagnostic agent for Alzheimer's disease containing the compound. The compound is represented by the following formula (1) or a salt thereof: | 09-30-2010 |
20100216994 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME - The invention provides a reagent which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid. | 08-26-2010 |
20100092387 | Novel Compound Having Affinity For Amyloid - A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): | 04-15-2010 |
20100074480 | DEVICE FOR GENERATING ALTERNATIVE OF NORMAL BRAIN DATABASE | 03-25-2010 |
20100028258 | Radioactive Diagnostic Imaging Agent - A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, whilst the pH is kept at 2.0-5.9. | 02-04-2010 |
20100016626 | PROCESS FOR PRODUCTION OF PRECURSOR COMPOUND FOR RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND - A process is provided for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of FACBC, a base is allowed to present in the reaction system to produce a syn-leaving group adduct, which is unreactive with the base and is highly stable, and an anti-leaving group adduct which can react with the base to form a water-soluble compound. By employing a purification method utilizing such a difference in solubility, the syn-leaving group adduct can be separated selectively. The base may be a linear- or branched-chain primary to tertiary alkylamine having 1 to 10 carbon atoms, a nitrogen-containing heterocyclic compound with 2 to 20 carbon atoms, and a nitrogen-containing hetero aromatic compound with 2 to 20 carbon atoms. | 01-21-2010 |
20090290765 | Neurodegenerative Disease Detection Method, Detecting Program, and Detector - A method of detecting a neurodegenerative disease includes (a) a standardization step of creating a first image by applying anatomical standardization to a brain nuclear medical image; (b) a conversion step of creating a second image by converting the pixel value of each pixel of an image based on the first image into a z score or a t value; (c) an addition step of calculating the sum of the pixel values of individual pixels in a predetermined region of interest in the second image; and (d) a detection step of obtaining the results of the detection of the neurodegenerative disease through an operation of comparison of the sum with a predetermined threshold. | 11-26-2009 |
20090281294 | PROCESS FOR PRODUCTION OF COMPOUND LABELED WITH RADIOACTIVE FLUORINE - A process for the production of [ | 11-12-2009 |
20090252680 | NOVEL COMPOUND WITH AFFINITY FOR AMYLOID - A compound represented by the following formula or a salt thereof: | 10-08-2009 |
20090252679 | Novel Compound Having Affinity for Amyloid - The present invention provides a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagencity. Provided is a compound represented by the following formula (1) or a salt thereof: | 10-08-2009 |
20090198085 | Process for Production of Radioactive Fluorine-Labeled Organic Compound - A process is provided for producing [ | 08-06-2009 |
20090148019 | Image Processing Method, Image Processing Program, and Image Processing Device - An image processing method is provided as one for creating a fused image automatically and with high overlapping accuracy. | 06-11-2009 |
20090105489 | NOVEL ORGANIC COMPOUND AND METHOD FOR PRODUCING RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND USING THE SAME - It is intended to provide a labeling precursor compound used for selectively producing radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acids, and to provide a process for producing a radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acid using the labeling precursor compound. A labeling precursor is used in which a phthalimide group is used as a protective group for protecting the amino group. The syn-form of the radioactive halogen-substituted 1-amino-3-cyclobutane-carboxylic acid can be selectively produced by labeling the labeling precursor with a radioactive halogen followed by deprotecting. | 04-23-2009 |
20090030192 | Process for production of compound labeled with radioactive fluorine - A process for the production of [ | 01-29-2009 |
20080281121 | Precursor Compound of Radioactive Halogen-Labeled Organic Compound - It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [ | 11-13-2008 |
20080267868 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex - A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [ | 10-30-2008 |